Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells

International Journal of Cancer

Volumn 105, Issue 2, 2003, Pages 165-175

  Smalley, Keiran S M ^a,b   Eisen, Tim G ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b WISTAR INSTITUTE   (United States)

Author keywords

B16; FTI; FTS; MAP Kinase; Melanoma

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; CISPLATIN; FARNESYLTHIOSALICYLIC ACID; LONAFARNIB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RETINOBLASTOMA PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL STRAIN 3T3; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOSTASIS; HUMAN; HUMAN CELL; MELANOMA; PRIORITY JOURNAL;

3T3 CELLS; ACTINS; ALKYL AND ARYL TRANSFERASES; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL DIVISION; CISPLATIN; COLONY-FORMING UNITS ASSAY; DRUG SYNERGISM; ENZYME INHIBITORS; FARNESOL; FARNESYLTRANSTRANSFERASE; HUMANS; IN SITU NICK-END LABELING; MELANOMA; MICE; MICROSCOPY, CONFOCAL; MITOGEN-ACTIVATED PROTEIN KINASES; PIPERIDINES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDINES; RETINOBLASTOMA PROTEIN; SALICYLIC ACIDS; SKIN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0037431539     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11064     Document Type: Article

References (49)

1. Satyamoorthy K, Bogenrieder T, Herlyn M. No longer a molecular black box: new clues to apoptosis and drug resistance in melanoma. Trends Mol Med 2001;7:191-4.
2. Helmbach H, Rossmann E, Kern MA, Schadendorf D. Drug-resistance in human melanoma. Int. J Cancer 2001;93:617-22.
3. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, McCombie R, Herman JG, Gerald WL, Lazebnikm YA, Cordon-Cardo C, Lowe SW. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001;409:207-11.
4. Leiter U, Schmid RM, Kaskel P, Peter RU, Krahn G. Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma. Arch Dermatol Res 2000;292:225-32.
5. Grover R, Wilson GD. Bcl-2 expression in malignant melanoma and its prognostic significance. Eur J Surg Oncol 1996;22:347-9.
6. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol 1999;17:2941-53.
7. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
8. Jansen B, Schlagbauer-Wadl H, Eichler HG, Wolff K, van Elsas A, Schrier PI, Pehamberger H. Activated N-ras contributes to the chemoresistance of human melanoma in severe combined immunodeficiency (SCID) mice by blocking apoptosis. Cancer Res 1997;57:362-5.
9. Carr J, MacKie RM. Point mutations in the N-ras oncogene in malignant melanoma and congenital naevi. Br J Dermatol 1994;131:72-7.
10. Tsao H, Zhang X, Fowlkes K, Haluska FG. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res 2000;60:1800-4.
11. Mattei S, Colombo MP, Melani C, Silvani A, Parmiani G, Herlyn M. Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int J Cancer 1994;56:853-7.
12. , Lazar-Molnar E, Hegyesi H, Toth S, Falus A. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 2000;12:547-54.
13. Smalley KSM, Eisen TG. Farnesyl thiosalicylic acid inhibits the growth of melanoma cells through a combination of cytostatic and pro-apoptotic effects. Int J Cancer 2002;98:514-22.
14. Sepp-Lorenzino L, Rosen N. A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells. J Biol Chem 1998;273:20243-51.
15. Ashar HR, James L, Gray K, Carr D, McGuirk M, Maxwell E, Black S, Armstrong L, Doll RJ, Taveras AG, Bishop WR, Kirschmeier P. The farnesyl transferase inhibitor SCH 66336 induces a G(2)→M or G(1) pause in sensitive human tumour cell lines. Exp Cell Res 2001;262:17-27.
16. Suzuki N, Urano J, Tamanoi F. Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells. Proc Natl Acad Sci USA 1998;95:15356-61.
17. Barrington RE, Subler MA, Rands E, Omer CA, Miller PJ, Hundley JE, Koester SK, Troyer DA, Bearss DJ, Conner MW, Gibbs JB, Hamilton K, et al. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol Cell Biol 1998;18:85-92.
18. Du W, Liu A, Prendergast GC. Activation of the PI3′K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors. Cancer Res 1999;59:4208-12.
19. Edmatasu H, Gau C-L, Nemoto T, Guo L, Tamanoi F. Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines. Oncogene 2000;19:3059-68.
20. Moasser MM, Sepp-Lorenzino L, Kohl NE, Oliff A, Balog A, Su DS, Danishefsky SJ, Rosen N. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to Taxo1 and epothilones. Proc Natl Acad Sci USA 1998;95:1369-74.
21. Shi B, Yaremko B. Hajian G, Terracina G, Bishop WR, Liu M, Nielsen LL. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo. Cancer Chemother Pharmacol 2000;46:387-93.
22. Hoover RR, Mahon FX, Melo JV, Daley GQ. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood 2002;100:1068-71.
23. Delmas C, Heliez C, Cohen-Jonathan E, End D, Bonnet J, Favre G. Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation. Int J Cancer 2002;100:43-8.
24. Liu M, Bryant MS, Chen J, Lee S, Yaremko B, Lipari P, Malkowski M, Ferrari E, Nielson L, Prioli N, Dell J, Sinha D, et al. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res 1998;58:4947-56.
25. Sun J, Blaskovich MA, Knowles D, Qian Y, Ohkanda J, Bailey RD, Hamilton AD, Sebti SM. Anti-tumour efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranyltrasnferase. 1. Combination therapy with the cytotoxic agents cisplatin, Taxo1 and gemcitabine. Cancer Res 1999;59:4919-26.
26. Adjei AA, Davis JN, Bruzek LM, Erlichman C, Kaufmann SH. Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. Clin Cancer Res 2001;7:1438-45.
27. Adjei AA, Davis JN, Erlichman C, Svingen PA, Kaufmann SH. Comparison of potential markers of farnesyltransferase inhibition. Clin Cancer Res 2000;6:2318-25.
28. Suzuki N, Del Villar K, Tamanoi F. Farnesyltransferase inhibitors induce dramatic morphological changes of KNRK cells that are blocked by microtubule interfering agents. Proc Natl Acad Sci USA 1998;95:10499-504.
29. Feldkamp MM, Lau N, Guha A. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects. Oncogene 1999;18:7514-26.
30. Hall A. Rho GTPases and the actin cytoskeleton. Science 1998;279:509-14.
31. Sahai E, Marshall CJ. Rho-GTPases and cancer. Nat Rev Cancer 2002;2:133-42.
32. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev 1998;12:2245-62.
33. DiCiommo D, Gallie BL, Bremner R. Retinoblastoma: the disease, gene and protein provide critical leads to understand cancer. Semin Cancer Biol 2000;10:255-69.
34. Bartkova J, Luka J, Guldberg P, Alsner J, Kirkin AF, Zeuthen J, Bartek J. The p16-cyclin D/Cdk-4-pRB pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 1996;56:5475-83.
35. Halaban R, Cheng E, Smicun Y, Germino J. Deregulated E2F transcriptional activity in autonomously growing melanoma cells. J Exp Med 2000;191:1005-15.
36. Mohammed MQ, Retsas S. Oxaliplatin is active in vitro against human melanoma cell lines: comparison with cisplatin and carboplatin. Anticancer Drugs 2000;11:859-63.
37. Helmbach H, Kern MA, Rossmann E, Renz K, Kissel C, Gschwendr B, Schadendorf D. Drug resistance towards etoposide and cisplatin in human melanoma cells is associated with drug-dependent apoptosis deficiency. J Invest Dermatol 2002;118:923-32.
38. Smalley K Eisen T. The involvement of p38 mitogen-activated protein kinase in the α-melanocyte stimulating hormone (α-MSH)-induced melanogenic and anti-proliferative effects in B16 murine melanoma cells. FEBS Lett 2000;476:198-202.
39. Smalley KSM, Eisen TG. Differentiation of human melanoma cells through p38 MAP kinase is associated with decreased retinoblastoma protein phosphorylation and cell cycle arrest. Melanoma Res 2002:12:187-92.
40. Gana-Weisz M, Haklai R, Marciano D, Egozi Y, Ben-Baruch G, Kloog Y. The Ras antagonist S-farnesylthiosalicylic acid induces inhibition of MAPK activation. Biochem Biophys Res Commun 1997;239:900-4.
41. Satyamoorthy K, Li G, Vaidya B, Patel D, Herlyn M. Insulin-like growth factor-1 induces survival and growth of biologically early melanoma cells through both the mitogen-activated protein kinase and β-catenin pathways. Cancer Res 2001;61:7318-24.
42. McGill GG, Horstmann M, Widlund HR, Du J, Motyckova G, Nishimura EK, Lin Y-L, Ramaswamy S, Avery W, Ding H-F, Jordan SA, Jackson IJ, et al. Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 2002;109:707-18.
43. Persons DL, Yazlovitskaya EM, Cui W, Pelling J. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase kinase activity increases sensitivity to cisplatin. Clin Cancer Res 1999;5:1007-14.
44. Mitsui H, Takuwa N, Maruyama T, Maekawa H, Hirayama Sawatari T, Hashimoto N, Takuwa Y, Kimura S. The Mek1-ERK MAP kinase pathway and the PI 3-kinase-AKT pathway independently mediate anti-apoptotic signals in HEPG2 liver cancer cells. Int J Cancer 2001;92:55-62.
45. Mandic A, Viktorsson K, Heiden T, Hansson J, Shoshan MC. The MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis. Melanoma Res 2001;11:11-9.
46. Prendergast GC. Actin' up: RhoB in cancer and apoptosis. Nat Rev Cancer 2001;1:162-8.
47. Du W, Prendergast GC. Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors. Cancer Res 1999;59:5492-6.
48. Liu A, Du W, Liu JP, Jessell TM, Prendergast GC. RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors. Mol Cell Biol 2000;20:6105-13.
49. Liu AX, Rane N, Liu JP, Prendergast GC. RhoB is dispensable for mouse development, but it modifies susceptibility to tumor formation as well as cell adhesion and growth factor signaling in transformed cells. Mol Cell Biol 2001;21:6906-12.